title: Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
authors.affiliation: Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria guntram.schernthaner@meduniwien.ac.at.
authors.forename: Guntram
authors.initials: G
authors.lastname: Schernthaner
authors.affiliation: Department of Internal Medicine, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: Avivit
authors.initials: A
authors.lastname: Cahn
authors.affiliation: Department of Internal Medicine, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: Itamar
authors.initials: I
authors.lastname: Raz
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004151:Dipeptides / Q000627:therapeutic use; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D006333:Heart Failure / Q000453:epidemiology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use; D012307:Risk Factors; D000068900:Sitagliptin Phosphate / Q000627:therapeutic use; D014498:Uracil / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D010880:Piperidines; D014498:Uracil; C502994:saxagliptin; C520853:alogliptin; D000218:Adamantane; D000068900:Sitagliptin Phosphate